MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis
2017/01/08 by Bishuang Cai, Edward B. Thorp, Amanda C. Doran +6 · 29 citations
Immunology and Microbiology · Medicine · #Phagocytosis and Immune Regulation #Biomarkers in Disease Mechanisms #Apelin-related biomedical research
paper · pdf · doi:10.1172/jci90520
Abstract
Atherothrombotic vascular disease is often triggered by a distinct type of atherosclerotic lesion that displays features of impaired inflammation resolution, notably a necrotic core and thinning of a protective fibrous cap that overlies the core. A key cause of plaque necrosis is defective clearance of apoptotic cells, or efferocytosis, by lesional macrophages, but the mechanisms underlying defective efferocytosis and its possible links to impaired resolution in atherosclerosis are incompletely understood. Here, we provide evidence that proteolytic cleavage of the macrophage efferocytosis receptor c-Mer tyrosine kinase (MerTK) reduces efferocytosis and promotes plaque necrosis and defective resolution. In human carotid plaques, MerTK cleavage correlated with plaque necrosis and the presence of ischemic symptoms. Moreover, in fat-fed LDL receptor-deficient (Ldlr-/-) mice whose myeloid cells expressed a cleavage-resistant variant of MerTK, atherosclerotic lesions exhibited higher macrophage MerTK, lower levels of the cleavage product soluble Mer, improved efferocytosis, smaller necrotic cores, thicker fibrous caps, and increased ratio of proresolving versus proinflammatory lipid mediators. These findings provide a plausible molecular-cellular mechanism that contributes to defective efferocytosis, plaque necrosis, and impaired resolution during the progression of atherosclerosis.
Cited by
- Palmitic acid alters enhancers/super-enhancers near inflammatory and efferocytosis-associated genes in human monocytes
- GATA2 induces a stem cell–like transcriptional program in macrophages that promotes an atherogenic phenotype
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- Efferocytosis in Health and Disease
- MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury. [europepmc]
- Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages. [europepmc]
- Monocyte-Macrophages and T Cells in Atherosclerosis. [europepmc]
- Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. [europepmc]
- Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis. [europepmc]
- The role of non-resolving inflammation in atherosclerosis. [europepmc]
- MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. [europepmc]
- Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2). [europepmc]
- Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice. [europepmc]
- Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. [europepmc]
- Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology. [europepmc]
- Foam Cells: One Size Doesn't Fit All. [europepmc]
- Efferocytosis in health and disease. [europepmc]
- Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. [europepmc]
- Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. [europepmc]
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. [europepmc]
- The role of phosphatidylserine recognition receptors in multiple biological functions. [europepmc]
- Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury. [europepmc]
- Targeting inflammation in atherosclerosis - from experimental insights to the clinic. [europepmc]
- Macrophage Plasticity and Atherosclerosis Therapy. [europepmc]
- Macrophages: The Good, the Bad, and the Gluttony. [europepmc]
- Efferocytosis induces macrophage proliferation to help resolve tissue injury. [europepmc]
- Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? [europepmc]
- Drugging the efferocytosis process: concepts and opportunities. [europepmc]
- Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. [europepmc]
Related